ClinicalTrials.gg
RecruitingNCT07748767Updated Nov 19, 2026

Micro-nanoplastic Exposure and Coronary Microcirculatory Dysfunction as Well as Cardiovascular Outcomes

An observational study in Coronary Microvascular Dysfunction (CMD), Microplastic Exposure and Nanoplastics, sponsored by Beijing Anzhen Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Beijing Anzhen Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 19, 2026Now RecruitingFirst site in China+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
184
Ages
18 Years and older
Sex
All
01

Study summary

With strict quality control procedures applied throughout microplastic testing, this study will assess the association between baseline circulating micro-nanoplastic exposure and coronary microvascular dysfunction, as well as subsequent long-term cardiovascular outcomes.

Read the detailed description

Using a prospective cohort study design, this study will enroll patients with clinical indications scheduled for invasive coronary angiography and coronary functional assessment. With a two-tiered framework of "pre-intervention baseline exposure assessment + procedural contamination quantification", it will be the first study to systematically evaluate the dose-response relationship between circulating microplastics and nanoplastics (MNPs) levels and coronary microvascular dysfunction (CMD). Through 2 years of follow-up, the effect of MNPs on the long-term prognosis of patients with CMD will also be assessed.

Multi-modal omics technologies including pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS), laser direct infrared spectroscopy (LDIR), and scanning electron microscopy coupled with energy dispersive X-ray spectroscopy (SEM-EDS) will be applied for the qualitative and quantitative detection of MNPs. The index of microcirculatory resistance (IMR) and coronary flow reserve (CFR), measured via the invasive thermodilution method recommended by the European Society of Cardiology (ESC), will be used to define and evaluate CMD.

The core innovations of this protocol are twofold:

The key blood samples for exposure measurement are strictly collected before any medical procedures are performed after admission, to maximally eliminate the confounding bias from iatrogenic interference in baseline MNPs exposure quantification.

A three-level blank quality control system (procedural blank, environmental blank, device blank) is established to realize full-process monitoring and quantification of iatrogenic contamination.

The entire study design strictly adheres to current technical recommendations and industry consensus in clinical practice, and demonstrates high feasibility, reproducibility, and reliability.

02

Conditions studied

  • Coronary Microvascular Dysfunction (CMD)
  • Microplastic Exposure
  • Nanoplastics
  • MACE
03

In context

Lead sponsor

Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients older than 18 years old, with clinical indications for planned invasive coronary angiography and coronary functional assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18;
  • Patients with clinical indications for undergoing invasive coronary angiography and coronary functional assessment (including fractional flow reserve [FFR], CFR, and IMR);
  • Voluntarily sign the written form.

Exclusion criteria

Exclusion Criteria:

  • The surgeon (or attending physician) determines that the patient is not suitable for or cannot tolerate a coronary physiological examination;
  • Intraoperative coronary angiography reveals a stenosis of>90% in any non-left main coronary artery lumen or a stenosis of>50% in the left main coronary artery lumen;
  • \<35% or cardiogenic shock or cardiac arrest;
  • Previous history of invasive procedures/treatments;
  • Active inflammatory diseases;
  • Connective tissue disease;
  • History of malignant tumors;
  • Expected lifespan \<2 years;
  • Pregnancy or lactation;
  • Subjects who refuse to comply with the pollution control measures set in this study;
  • Currently participating in other interventional clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
184 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Micro-nanoplastic Exposure and CVOT

    According to the baseline circulating MNPs exposure level of the patients, participants will be categorized into the high-exposure group and low-exposure group using the median value as the cutoff point.

    Other: micro-nanoplastic examination · Procedure: Microvascular Function Examination

Interventions

  • Othermicro-nanoplastic examination

    In this prospective cohort study, the investigators plan to perform a low-contamination protocol for the detection of circulating micro-nanoplastic particles in eligible subjects prior to the administration of invasive coronary angiography and concomitant coronary microvascular function assessment, so as to clarify the impact of micro-nanoplastic exposure status on coronary microvascular function and long-term prognosis.

  • ProcedureMicrovascular Function Examination

    Using a catheter to perform invasive coronary functional assessment, including flow fraction reserve(FFR), coronary flow reserve (CFR) and index of microcirculation resistance (IMR)

06

What researchers measure

Primary outcomes

  1. Baseline Peripheral Circulatory MNPs Concentration(μg/g, particles/ml)

    Using multi-modal omics methodologies (Py-GC/MS, LDIR, and SEM-EDS), the investigators will evaluate the correlation between the total baseline peripheral circulatory concentration of MNPs and the baseline concentration of each specific particle type (reported as mass concentration in μg/g and particle count in particles/mL) in peripheral circulating blood and coronary sinus blood, and baseline coronary microvascular function

    Time frame: baseline

  2. Coronary Microvascular Function

    Using invasive functional examinations (Coronary Flow Reverse, CFR and Index of Microcirculatory Resistance, IMR) to evaluate coronary microvascular function. Coronary Microvascular Dysfunction (CMD) is diagnosed by CFR\<2.0 and IMR≥25.

    Time frame: baseline

Secondary outcomes

  1. 2 years Follow-up MACE

    Major Adverse Cardiovascular Events (MACE) is defined as a composition endpoint including all-cause death, non-fatal stroke, non-fatal myocardial infarction, hospitalization due to unstable angina, or heart failure events

    Time frame: 2 years

  2. Baseline Intracoronary MNPs Concentration(μg/g, particles/ml)

    Using multi-modal omics methodologies (Py-GC/MS, LDIR, and SEM-EDS), the investigators will evaluate the correlation between the total baseline intracoronary concentration of MNPs and the baseline concentration of each specific particle type (reported as mass concentration in μg/g and particle count in particles/mL) in both peripheral circulating blood and coronary sinus blood, and baseline coronary microvascular function.

    Time frame: Baseline

Other outcomes

  1. Baseline Peripheral MNPs Subpopulations

    Using multi-modal omics methodologies (Py-GC/MS, LDIR, SEM-EDS), the investigators will evaluate the correlations between CMD and multiple variables of MNPs in both peripheral circulating blood and coronary sinus blood, including MNP particle counts, morphological characteristics of each specific particle type (particle size, shape, polymer type, surface charge, etc.)

    Time frame: Baseline

  2. Baseline Intracoronary MNPs Subpopulations

    Using multi-modal omics methodologies (Py-GC/MS, LDIR, SEM-EDS), the investigators will evaluate the correlations between CMD and multiple variables of MNPs in both peripheral circulating blood and coronary sinus blood, including MNP particle counts, morphological characteristics of each specific particle type (particle size, shape, polymer type, surface charge, etc.)

    Time frame: Baseline

  3. Baseline Circulatory Inflammation Biomarkers

    Circulatory Inflammation Biomarkers includes interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), procalcitonin (PCT), among other related molecular indicators.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jan 2027 → Sep 2026, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2026
First posted
Aug 6, 2026
StartActual
Sep 8, 2026was Jan 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in China
Show site
  • Beijing Anzhen Hospital · Beijing, China
Nov 19, 2026
Start date
Jan 1, 2027→Sep 8, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Beijing Anzhen Hospital · Beijing, China
    Start date Jan 1, 2027→Sep 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07748767
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Sep 8, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Zhijian Wang
Contact
nongfu1975@126.com
010 6441 2431

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion